{"schema_version":"1","generated_at":"2026-11-04T18:06:17.228Z","data_as_of":null,"url":"https://www.findmykol.com/kol/sheheryar-kabraji","json_url":"https://www.findmykol.com/kol/sheheryar-kabraji/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"sheheryar-kabraji","name":"Sheheryar Kabraji","credential":"BM, BCH","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Roswell Park Comprehensive Cancer Center","institution_url":"https://www.findmykol.com/institution/roswell-park-comprehensive-cancer-center","city":"Buffalo","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1326369562","orcid":"0000-0002-5315-7103","openalex":"A5022623760"},"summary":"Sheheryar Kabraji is an Oncology physician affiliated with Roswell Park Comprehensive Cancer Center. OpenAlex indexes 71 publications with 1,643 citations (h-index 15); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":71,"cited_by_count":1643,"h_index":15,"latest_activity_year":2026,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06434064","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Roswell Park Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT06434064","trial_url":"https://www.findmykol.com/trial/NCT06434064"},{"nct":"NCT04348747","title":"Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","phase":"PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Roswell Park Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT04348747","trial_url":"https://www.findmykol.com/trial/NCT04348747"}],"source":"trials"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":4,"shown":3,"withheld":1,"rows":[{"payer":"Merck & Co.","program_year":2025,"amount_usd":245391.44,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1326369562"},{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":2240,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1326369562"},{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":960,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1326369562"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1326369562","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":2,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":67.1,"drugs":[{"name":"Letrozole","share_pct":100}],"max_beneficiaries":31},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":32.9,"drugs":[{"name":"Kisqali","share_pct":57.7},{"name":"Ibrance","share_pct":42.3}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond","year":2026,"journal":"Nature Reviews Drug Discovery","source_url":"https://doi.org/10.1038/s41573-026-01431-5","status":"verified"},{"title":"Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors","year":2026,"journal":"JCO Precision Oncology","source_url":"https://doi.org/10.1200/po-25-00346","status":"verified"},{"title":"Real-world analysis of adjuvant abemaciclib in high-risk HR+/HER2− early breast cancer.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.e12529","status":"verified"},{"title":"GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.10548","status":"verified"},{"title":"Abstract PS4-03-20: Spatial and biomarker associations of CD83, a promising CAR-T target for breast cancer","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-ps4-03-20","status":"verified"}],"source":"works"},"contact":{"address_1":"ELM AND CARLTON ST","city":"Buffalo","state":"NY","zip":"142630001","phone":"716-845-2300","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1326369562","source":"identity"},"similar":[{"name":"Igor Puzanov","slug":"igor-puzanov","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/igor-puzanov","json_url":"https://www.findmykol.com/kol/igor-puzanov/profile.json"},{"name":"Philip McCarthy","slug":"philip-mccarthy","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/philip-mccarthy","json_url":"https://www.findmykol.com/kol/philip-mccarthy/profile.json"},{"name":"Saby George","slug":"saby-george","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/saby-george","json_url":"https://www.findmykol.com/kol/saby-george/profile.json"},{"name":"Eunice Wang","slug":"eunice-wang","institution":"Roswell Park Comprehensive Cancer Center","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/eunice-wang","json_url":"https://www.findmykol.com/kol/eunice-wang/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":1,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2023-02-15","provider_certified":"2023-02-15","collected_at":"2026-11-04T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}